Calcitonin treatment for neuropathic pain after spinal cord injury
Effect of Early Calcitonin Therapy on Incidence and Severity of Neuropathic Pain After Spinal Cord Injury
This study is testing if calcitonin can help reduce the pain that people experience after a spinal cord injury compared to a placebo.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Tanta, Gharbia Governorate) |
| Trial ID | NCT05805683 on ClinicalTrials.gov |
What this trial studies
This prospective randomized double-blinded study aims to evaluate the effects of early calcitonin treatment on the incidence and severity of neuropathic pain following spinal cord injury. The study will categorize pain into various types and assess how calcitonin, known for its effectiveness in managing acute pain in other conditions, can help in this context. Participants will be randomly assigned to receive either calcitonin or a placebo, allowing for a controlled comparison of outcomes.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who have sustained a spinal cord injury at any level and degree of completeness shortly after the trauma.
Not a fit: Patients who are currently taking anticonvulsants, have existing neuropathic pain, or have a history of allergic reactions to calcitonin may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly reduce the incidence and severity of neuropathic pain in patients with spinal cord injuries.
How similar studies have performed: Previous studies have shown calcitonin to be effective in managing acute pain in various conditions, suggesting potential for success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged ≥18 years, with spinal cord injury at any level and any degree of completeness in the early stage of trauma. Exclusion Criteria: * Intake of anticonvulsants medications. * Evidence of neuropathic pain. * Evidence of previous allergic reaction to calcitonin. * Patients with renal, hepatic and cardiac dysfunction or neurological disorders . * brain damage or major trauma to extremities or abdomen.
Where this trial is running
Tanta, Gharbia Governorate
- Tanta University — Tanta, Gharbia Governorate, Egypt (Recruiting)
Study contacts
- Study coordinator: Osama M Rehab, MD
- Email: osamarehab@med.tanta.edu.eg
- Phone: 00201095210806
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.